Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance

Drug Resistance Updates

Volumn 23, Issue , 2015, Pages 20-54

  Taddia, Laura ^a   D'Arca, Domenico ^a   Ferrari, Stefania ^a   Marraccini, Chiara ^a   Severi, Leda ^a   Ponterini, Glauco ^a   Assaraf, Yahuda G ^b   Marverti, Gaetano ^a   Costi, Maria Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anticancer drugs; Chemoresistance; Clinical trials; Folate dependent enzymes; Folate metabolism; Holistic reductionistic approach; Pathways perturbations; Personalized Medicine; Proteomic; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLIC ACID; METHOTREXATE; PEMETREXED; PRALATREXATE; RALTITREXED; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ENZYME INHIBITOR; FOLIC ACID ANTAGONIST; TUMOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL CULTURE; CELL MATURATION; DNA REPAIR; DNA SYNTHESIS; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RNA PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM PROTEINS; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; THYMIDYLATE SYNTHASE;

EID: 84948452098     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.10.003     Document Type: Article

References (348)

1. S. Agarwal, C.M. Bell, S.B. Rothbart, and R.G. Moran AMPK control of mTORC1 is p53- and TSC2-independent in pemetrexed-treated carcinoma cells J. Biol. Chem. 290 42 2015
2. T. Akasaka, M. Tsujii, J. Kondo, Y. Hayashi, J. Ying, Y. Lu, M. Kato, T. Yamada, S. Yamamoto, T. Inoue, Y. Tsujii, A. Maekawa, T. Fujinaga, E. Shiraishi, S. Hiyama, T. Inoue, S. Shinzaki, K. Watabe, T. Nishida, H. Iijima, and T. Takehara 5FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53 mutated colon cancer cells Int. J. Oncol. 46 2015 63 70
3. H. Akhdar, P. Loyer, C. Rauch, A. Corlu, A. Guillouzo, and F. Morel Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells Eur. J. Cancer 45 2009 2219 2227
4. T. Aki, K. Yamaguchi, T. Fujimiya, and Y. Mizukami Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2 Oncogene 22 2003 8529 8535
5. R.I. Al-Safi, S. Odde, Y. Shabaik, and N. Neamati Small-molecule inhibitors of APE1 DNA repair function: an overview Curr. Mol. Pharmacol. 5 2012 14 35
6. C.J. Allegra, B.A. Chabner, J.C. Drake, R. Lutz, D. Rodbard, and J. Jolivet Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates J. Biol. Chem. 260 1985 9720 9726
7. B. Alvarez, A.C. Martinez, B.M. Burgering, and A.C. Carrera Forkhead transcription factors contribute to execution of the mitotic programme in mammals Nature 413 2001 744 747
8. Q. An, P. Robins, T. Lindahl, and D.E. Barnes 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity Cancer Res. 67 2007 940 945
9. T. Ando, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, N. Sugito, R. Mori, R. Ogawa, T. Katada, and Y. Fujii Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines Dis. Esophagus 21 2008 15 20
10. G. Aprile, M. Mazzer, S. Moroso, and F. Puglisi Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer Anticancer Drugs 20 2009 217 229
11. A. Argiris, E. Pennella, A. Koustenis, A.M. Hossain, and C.K. Obasaju Pemetrexed in head and neck cancer: a systematic review Oral Oncol. 49 2013 492 501
12. C.N. Arnold, A. Goel, and C.R. Boland Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines Int. J. Cancer 106 2003 66 73
13. Y.G. Assaraf Molecular basis of antifolate resistance Cancer Metastasis Rev. 26 2007 153 181
14. Y.G. Assaraf The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis Drug Resist. Updat. 9 2006 227 246
15. Y.G. Assaraf, C.P. Leamon, and J.A. Reddy The folate receptor as a rational therapeutic target for personalized cancer treatment Drug Resist. Updat. 17 2014 89 95
16. C.G. Azzoli, L.M. Krug, J. Gomez, V.A. Miller, M.G. Kris, M.S. Ginsberg, R. Henry, J. Jones, L. Tyson, M. Dunne, B. Pizzo, A. Farmer, E. Venkatraman, R. Steffen, and F.M. Sirotnak A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors Clin. Cancer Res. 13 2007 2692 2698
17. P. Baas, A. Ardizzoni, F. Grossi, K. Nackaerts, G. Numico, E. Van Marck, M. van de Vijver, F. Monetti, M.J. Smid-Geirnaerdt, N. van Zandwijk, C. Debruyne, C. Legrand, and G. Giaccone The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992) Eur. J. Cancer 39 2003 353 357
18. J.E. Baggott, W.H. Vaughn, and B.B. Hudson Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide Biochem. J. 236 1986 193 200
19. D. Banerjee, P. Mayer-Kuckuk, G. Capiaux, T. Budak-Alpdogan, R. Gorlick, and J.R. Bertino Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase Biochim. Biophys. Acta 1587 2002 164 173
20. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, and Y.K. Kang Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
21. A.R. Bapat, C. Zarow, and P.V. Danenberg Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides J. Biol. Chem. 258 1983 4130 4136
22. K.W. Barbour, S.H. Berger, and F.G. Berger Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase Mol. Pharmacol. 37 1990 515 518
23. K.W. Barbour, D.K. Hoganson, S.H. Berger, and F.G. Berger A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2′-deoxyuridine in mammalian and bacterial cells Mol. Pharmacol. 42 1992 242 248
24. M.J. Barnes, E.J. Estlin, G.A. Taylor, G.W. Aherne, A. Hardcastle, J.J. McGuire, J.A. Calvete, J. Lunec, A.D. Pearson, and D.R. Newell Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines Clin. Cancer Res. 5 1999 2548 2558
25. J. Barthelmes, C. Ebeling, A. Chang, I. Schomburg, and D. Schomburg BRENDA, AMENDA and FRENDA: the enzyme information system in 2007 Nucleic Acids Res. 35 2007 D511 D514
26. A. Bellacosa, L. Cicchillitti, F. Schepis, A. Riccio, A.T. Yeung, Y. Matsumoto, E.A. Golemis, M. Genuardi, and G. Neri MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1 Proc. Natl. Acad. Sci. U.S.A. 96 1999 3969 3974
27. R.C. Benjamin, and D.M. Gill ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA J. Biol. Chem. 255 1980 10493 10501
28. S.H. Berger, K.W. Barbour, and F.G. Berger A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line Mol. Pharmacol. 34 1988 480 484
29. J.M. Berg JLT, and Lubert Stryer Biochemistry 2002 W.H. Freeman New York
30. S.H. Berger, and F.G. Berger Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumor cell lines Mol. Pharmacol. 34 1988 474 479
31. P. Biason, M. Visentin, R. Talamini, A. Stopar, G. Giorda, E. Lucia, E. Campagnutta, and G. Toffoli Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy Pharmacogenomics 13 2012 1609 1619
32. J.H. Bielas, M.W. Schmitt, A. Icreverzi, N.G. Ericson, and L.A. Loeb Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cells Hum. Gene Ther. 20 2009 1703 1707
33. O. Brenes, F. Arce, O. Gatjens-Boniche, and C. Diaz Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: possible mechanisms of cell resistance Biomed. Pharmacother. 61 2007 347 355
34. D.R. Budman Capecitabine Invest. New Drugs 18 2000 355 363
35. D.R. Budman, N.J. Meropol, B. Reigner, P.J. Creaven, S.M. Lichtman, E. Berghorn, J. Behr, R.J. Gordon, B. Osterwalder, and T. Griffin Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine J. Clin. Oncol. 16 1998 1795 1802
36. A.D. Bulgar, L.D. Weeks, Y. Miao, S. Yang, Y. Xu, C. Guo, S. Markowitz, N. Oleinick, S.L. Gerson, and L. Liu Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair Cell Death Dis. 3 2012 e252
37. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
38. A. Calascibetta, D. Cabibi, A. Martorana, G. Sanguedolce, L. Rausa, S. Feo, G. Dardanoni, and R. Sanguedolce Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer Anticancer Res. 24 2004 3875 3880
39. A. Calascibetta, F. Contino, S. Feo, G. Gulotta, M. Cajozzo, A. Antona, G. Sanguedolce, and R. Sanguedolce Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-fluorouracil drug response J. Nucleic Acids 2010 2010
40. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
41. M. Cantore, G. Fiorentini, G. Luppi, G. Rosati, R. Caudana, E. Piazza, G. Comella, C. Ceravolo, L. Miserocchi, A. Mambrini, A. Del Freo, D. Zamagni, C. Rabbi, and M. Marangolo Gemcitabine vs FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology J. Chemother. 16 2004 589 594
42. S.J. Caradonna, and Y.C. Cheng The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells Mol. Pharmacol. 18 1980 513 520
43. D.P. Carbone, K. Ding, H. Roder, J. Grigorieva, J. Roder, M.S. Tsao, L. Seymour, and F.A. Shepherd Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial J. Thorac. Oncol. 7 2012 1653 1660
44. D. Cardinale, G. Guaitoli, D. Tondi, R. Luciani, S. Henrich, O.M. Salo-Ahen, S. Ferrari, G. Marverti, D. Guerrieri, A. Ligabue, C. Frassineti, C. Pozzi, S. Mangani, D. Fessas, R. Guerrini, G. Ponterini, R.C. Wade, and M.P. Costi Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 108 2011 E542 E549
45. D. Cardinale, O.M. Salo-Ahen, G. Guaitoli, S. Ferrari, A. Venturelli, S. Franchini, R. Battini, G. Ponterini, R.C. Wade, and M.P. Costi Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding Protein Eng. Des. Sel. 23 2010 81 89
46. J.M. Carethers, D.P. Chauhan, D. Fink, S. Nebel, R.S. Bresalier, S.B. Howell, and C.R. Boland Mismatch repair proficiency and in vitro response to 5-fluorouracil Gastroenterology 117 1999 123 131
47. E. Carosati, G. Sforna, M. Pippi, G. Marverti, A. Ligabue, D. Guerrieri, S. Piras, G. Guaitoli, R. Luciani, M.P. Costi, and G. Cruciani Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors Bioorg. Med. Chem. 18 2010 7773 7785
48. C.W. Carreras, and D.V. Santi The catalytic mechanism and structure of thymidylate synthase Annu. Rev. Biochem. 64 1995 721 762
49. J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzen, and L. Saltz Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J. Clin. Oncol. 26 2008 2006 2012
50. S. Chattopadhyay, R. Zhao, S.A. Krupenko, N. Krupenko, and I.D. Goldman The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line Mol. Cancer Ther. 5 2006 438 449
51. I. Chau, and D. Cunningham Treatment in advanced colorectal cancer: what, when and how? Br. J. Cancer 100 2009 1704 1719
52. K.C. Chen, T.Y. Yang, C.C. Wu, C.C. Cheng, S.L. Hsu, H.W. Hung, J.W. Chen, and G.C. Chang Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway PLoS One 9 2014 e97888
53. Z.S. Chen, K. Lee, S. Walther, R.B. Raftogianis, M. Kuwano, H. Zeng, and G.D. Kruh Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system Cancer Res. 62 2002 3144 3150
54. S. Cheradame, M. Chazal, J.L. Fischel, P. Formento, N. Renee, and G. Milano Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activity Anticancer Drugs 10 1999 505 510
55. S. Choi, and J.L. Ku Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression Biochem. Biophys. Res. Commun. 412 2011 207 213
56. E. Chu, and C.J. Allegra The role of thymidylate synthase as an RNA binding protein Bioessays 18 1996 191 198
57. E. Chu, M.A. Callender, M.P. Farrell, and J.C. Schmitz Thymidylate synthase inhibitors as anticancer agents: from bench to bedside Cancer Chemother. Pharmacol. 52 Suppl. 1 2003 S80 S89
58. E. Chu, J.L. Grem, P.G. Johnston, and C.J. Allegra New concepts for the development and use of antifolates Stem Cells 14 1996 41 46
59. E. Chu, D.M. Koeller, J.L. Casey, J.C. Drake, B.A. Chabner, P.C. Elwood, S. Zinn, and C.J. Allegra Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 88 1991 8977 8981
60. E. Chu, D.M. Voeller, K.L. Jones, T. Takechi, G.F. Maley, F. Maley, S. Segal, and C.J. Allegra Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells Mol. Cell. Biol. 14 1994 207 213
61. J. Ciesla, T. Fraczyk, Z. Zielinski, J. Sikora, and W. Rode Altered mouse leukemia L1210 thymidylate synthase, associated with cell resistance to 5-fluoro-dUrd, is not mutated but rather reflects posttranslational modification Acta Biochim. Pol. 53 2006 189 198
62. J.F. Committee British National Formulary (BNF) 2013
63. S. Cortellino, D. Turner, V. Masciullo, F. Schepis, D. Albino, R. Daniel, A.M. Skalka, N.J. Meropol, C. Alberti, L. Larue, and A. Bellacosa The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity Proc. Natl. Acad. Sci. U.S.A. 100 2003 15071 15076
64. M.P. Costi, and S. Ferrari Update on antifolate drugs targets Curr. Drug Targets 2 2001 135 166
65. M.P. Costi, D. Tondi, M. Rinaldi, D. Barlocco, P. Pecorari, F. Soragni, A. Venturelli, and R.M. Stroud Structure-based studies on species-specific inhibition of thymidylate synthase Biochim. Biophys. Acta 1587 2002 206 214
66. N.J. Curtin, and A.N. Hughes Pemetrexed disodium, a novel antifolate with multiple targets Lancet Oncol. 2 2001 298 306
67. Y. Dai, and S. Grant Cyclin-dependent kinase inhibitors Curr. Opin. Pharmacol. 3 2003 362 370
68. Database, K.p., http://www.genome.jp/kegg/pathway.html.
69. B.C. Ding, T.L. Witt, B. Hukku, H. Heng, L. Zhang, and L.H. Matherly Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells Biochem. Pharmacol. 61 2001 665 675
70. S.L. Doong, and B.J. Dolnick 5-Fluorouracil substitution alters pre-mRNA splicing in vitro J. Biol. Chem. 263 1988 4467 4473
71. J.C. Drake, C.J. Allegra, R.G. Moran, and P.G. Johnston Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines Biochem. Pharmacol. 51 1996 1349 1355
72. S. Drori, G. Jansen, R. Mauritz, G.J. Peters, and Y.G. Assaraf Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake J. Biol. Chem. 275 2000 30855 30863
73. M. Ducreux, E. Mitry, M. Ould-Kaci, V. Boige, J.F. Seitz, R. Bugat, J.L. Breau, O. Bouche, P.L. Etienne, J.M. Tigaud, F. Morvan, E. Cvitkovic, and P. Rougier Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients Ann. Oncol. 15 2004 467 473
74. M. Ducreux, P. Rougier, J.P. Pignon, J.Y. Douillard, J.F. Seitz, R. Bugat, J.F. Bosset, Y. Merouche, J.L. Raoul, M. Ychou, A. Adenis, F. Berthault-Cvitkovic, and M. Luboinski A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma Ann. Oncol. 13 2002 1185 1191
75. S.J. Elledge, Z. Zhou, and J.B. Allen Ribonucleotide reductase: regulation, regulation, regulation Trends Biochem. Sci. 17 1992 119 123
76. H. Elsaleh, B. Powell, K. McCaul, F. Grieu, R. Grant, D. Joseph, and B. Iacopetta P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma Clin. Cancer Res. 7 2001 1343 1349
77. M.C. Etienne, S. Cheradame, J.L. Fischel, P. Formento, O. Dassonville, N. Renee, M. Schneider, A. Thyss, F. Demard, and G. Milano Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13 1995 1663 1670
78. D. Exinger, F.E. Bertrand Mennecier, J.-M. Limache, P. Dufour, and J.-E. Kurtz Multitargeted antifolate (Pemetrexed): a comprehensive review of its mechanisms of action,recent results and future prospects Cancer Ther. 1 2003 315 322
79. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N. Engl. J. Med. 238 1948 787 793
80. S. Ferrari, V. Losasso, and M.P. Costi Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family Chem. Med. Chem. 3 2008 392 401
81. V.D. Ferrari, V. Amoroso, F. Valcamonico, A. Fusi, E. Simoncini, L. Vasalli, G. Rangoni, A. Mambrini, P. Marpicati, E. Montini, and G. Marini Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study Am. J. Clin. Oncol. 27 2004 445 448
82. G. Findenig, R.M. Mader, M. Fritzer-Szekeres, G.G. Steger, W. Jaeger, and T. Szekeres Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine Oncol. Res. 8 1996 189 196
83. J.S. Finer-Moore, D.V. Santi, and R.M. Stroud Lessons and conclusions from dissecting the mechanism of a bisubstrate enzyme: thymidylate synthase mutagenesis, function, and structure Biochemistry 42 2003 248 256
84. J.A. Fischer, S. Muller-Weeks, and S.J. Caradonna Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase Cancer Res. 66 2006 8829 8837
85. K. Fizazi, H. Doubre, T. Le Chevalier, A. Riviere, J. Viala, C. Daniel, L. Robert, P. Barthelemy, A. Fandi, and P. Ruffie Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study J. Clin. Oncol. 21 2003 349 354
86. K. Fizazi, M. Ducreux, P. Ruffie, M. Bonnay, C. Daniel, J.C. Soria, C. Hill, A. Fandi, M. Poterre, M. Smith, and J.P. Armand Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer J. Clin. Oncol. 18 2000 2293 2300
87. W.F. Flintoff, H. Sadlish, R. Gorlick, R. Yang, and F.M. Williams Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas Biochim. Biophys. Acta 1690 2004 110 117
88. A.M. Forsthoefel, M.M. Pena, Y.Y. Xing, Z. Rafique, and F.G. Berger Structural determinants for the intracellular degradation of human thymidylate synthase Biochemistry 43 2004 1972 1979
89. S.J. Freemantle, A.L. Jackman, L.R. Kelland, A.H. Calvert, and J. Lunec Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694 Br. J. Cancer 71 1995 925 930
90. C.S. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schulz, D. Richards, R. Soufi-Mahjoubi, B. Wang, and J. Barrueco Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J. Clin. Oncol. 25 2007 4779 4786
91. H. Fukuda, N. Takiguchi, K. Koda, K. Oda, K. Seike, and M. Miyazaki Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients Cancer Invest. 24 2006 235 241
92. M.G. Fury, L.M. Krug, C.G. Azzoli, S. Sharma, N. Kemeny, N. Wu, M.G. Kris, and N.A. Rizvi A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors Cancer Chemother. Pharmacol. 57 2006 671 677
93. S.M. Gadgeel, and A. Wozniak Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer Clin. Lung Cancer 14 2013 322 332
94. A. Gangjee, Y. Qiu, W. Li, and R.L. Kisliuk Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates J. Med. Chem. 51 2008 5789 5797
95. D. Garg, S. Henrich, O.M. Salo-Ahen, H. Myllykallio, M.P. Costi, and R.C. Wade Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs J. Med. Chem. 53 2010 6539 6549
96. F. Genovese, A. Gualandi, L. Taddia, G. Marverti, S. Pirondi, C. Marraccini, P. Perco, M. Pela, R. Guerrini, M.R. Amoroso, F. Esposito, A. Martello, G. Ponterini, D. D'Arca, and M.P. Costi Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides J. Proteome Res. 13 2014 5250 5261
97. N. Gonen, and Y.G. Assaraf Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance Drug Resist. Updat. 15 2012 183 210
98. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin vs topotecan J. Clin. Oncol. 19 2001 3312 3322
99. M.S. Gordon, L.S. Rosen, D. Mendelson, R.K. Ramanathan, J. Goldman, L. Liu, Y. Xu, S.L. Gerson, S.P. Anthony, W.D. Figg, S. Spencer, B.J. Adams, C.P. Theuer, B.R. Leigh, and G.J. Weiss A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors Invest. New Drugs 31 2013 714 723
100. M. Goulian, B.M. Bleile, L.M. Dickey, R.H. Grafstrom, H.A. Ingraham, S.A. Neynaber, M.S. Peterson, and B.Y. Tseng Mechanism of thymineless death Adv. Exp. Med. Biol. 195 Pt B 1986 89 95
101. R.H. Grafstrom, B.Y. Tseng, and M. Goulian The incorporation of uracil into animal cell DNA in vitro Cell 15 1978 131 140
102. J. Green, Y. Dundar, S. Dodd, R. Dickson, and T. Walley Pemetrexed disodium in combination with cisplatin vs other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma Cochrane Database Syst. Rev. 2007 CD005574
103. F. Grosso, and G.V. Scagliotti Systemic treatment of malignant pleural mesothelioma Future Oncol. 8 2012 293 305
104. W. Gu, F.F. Fang, B. Li, B.B. Cheng, and C.Q. Ling Characterization and resistance mechanisms of a 5-fluorouracil-resistant hepatocellular carcinoma cell line Asian Pac. J. Cancer Prev. 13 2012 4807 4814
105. F. Gundling, M. Fuchs, L. Nowak, D. Antoni, E. Hoffmann, and W. Schepp "Iatrogenic acute coronary syndrome" - 59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil Z. Gastroenterol. 44 2006 975 979
106. X. Guo, E. Goessl, G. Jin, E.S. Collie-Duguid, J. Cassidy, W. Wang, and V. O'Brien Cell cycle perturbation and acquired 5-fluorouracil chemoresistance Anticancer Res. 28 2008 9 14
107. W. Hagmann, R. Jesnowski, R. Faissner, C. Guo, and J.M. Lohr ATP-binding cassette C transporters in human pancreatic carcinoma cell lines, upregulation in 5-fluorouracil-resistant cells Pancreatology 9 2009 136 144
108. C. Hahnvajanawong, J. Chaiyagool, W. Seubwai, V. Bhudhisawasdi, N. Namwat, N. Khuntikeo, B. Sripa, A. Pugkhem, and W. Tassaneeyakul Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil World J. Gastroenterol. 18 2012 3955 3961
109. K. Harada, T. Ferdous, and Y. Ueyama Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes Int. J. Oncol. 44 2014 1302 1308
110. M. Hazarika, R.M. White Jr., B.P. Booth, Y.C. Wang, D.Y. Ham, C.Y. Liang, A. Rahman, J.V. Gobburu, N. Li, R. Sridhara, D.E. Morse, R. Lostritto, P. Garvey, J.R. Johnson, and R. Pazdur Pemetrexed in malignant pleural mesothelioma Clin. Cancer Res. 11 2005 982 992
111. C. Heidelberger On the rational development of a new drug: the example of the fluorinated pyrimidines Cancer Treat. Rep. 65 Suppl. 3 1981 3 9
112. C. Heidelberger, N.K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R.J. Schnitzer, E. Pleven, and J. Scheiner Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
113. M.L. Hensley, J. Larkin, M. Fury, S. Gerst, D.F. Tai, P. Sabbatini, J. Konner, M. Orlando, T.L. Goss, and C.A. Aghajanian A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer Clin. Cancer Res. 14 2008 6310 6316
114. P.M. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, E. Harrison, H.U. Burger, B. Osterwalder, A.O. Wong, and R. Wong Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J. Clin. Oncol. 19 2001 2282 2292
115. J.H. Hooijberg, G.J. Peters, Y.G. Assaraf, I. Kathmann, D.G. Priest, M.A. Bunni, A.J. Veerman, G.L. Scheffer, G.J. Kaspers, and G. Jansen The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis Biochem. Pharmacol. 65 2003 765 771
116. S.M. Horwitz, Y.H. Kim, F. Foss, J.M. Zain, P.L. Myskowski, M.J. Lechowicz, D.C. Fisher, A.R. Shustov, N.L. Bartlett, M.L. Delioukina, T. Koutsoukos, M.E. Saunders, O.A. O'Connor, and M. Duvic Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 119 2012 4115 4122
117. J. Hoskins, and J.S. Butler RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p Genetics. 179 2008 323 330
118. C.T. Hsueh, D. Kelsen, and G.K.s. Schwartz UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner Clin. Cancer Res. 4 1998 2201 2206
119. C.T. Hughey, K.W. Barbour, F.G. Berger, and S.H. Berger Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase Mol. Pharmacol. 44 1993 316 323
120. R. Humeniuk, L.G. Menon, P.J. Mishra, R. Gorlick, R. Sowers, W. Rode, G. Pizzorno, Y.C. Cheng, N. Kemeny, J.R. Bertino, and D. Banerjee Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance Mol. Cancer Ther. 8 2009 1037 1044
121. R. Humeniuk, P.J. Mishra, J.R. Bertino, and D. Banerjee Epigenetic reversal of acquired resistance to 5-fluorouracil treatment Mol. Cancer Ther. 8 2009 1045 1054
122. I.T. Hwang, Y.M. Chung, J.J. Kim, J.S. Chung, B.S. Kim, H.J. Kim, J.S. Kim, and Y.D. Yoo Drug resistance to 5-FU linked to reactive oxygen species modulator 1 Biochem. Biophys. Res. Commun. 359 2007 304 310
123. D.R. Hyduke, and B.O. Palsson Towards genome-scale signalling network reconstructions Nat. Rev. Genet. 11 2010 297 307
124. K. Ikeda, K. Yoshisue, E. Matsushima, S. Nagayama, K. Kobayashi, C.A. Tyson, K. Chiba, and Y. Kawaguchi Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro Clin. Cancer Res. 6 2000 4409 4415
125. M. Inaba, J. Mitsuhashi, H. Sawada, N. Miike, Y. Naoe, A. Daimon, K. Koizumi, H. Tsujimoto, and M. Fukushima Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells Jpn J. Cancer Res. 87 1996 212 220
126. T. Ishikawa Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma World J. Gastroenterol. 14 2008 2797 2801
127. T. Ishikawa, F. Sekiguchi, Y. Fukase, N. Sawada, and H. Ishitsuka Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts Cancer Res. 58 1998 685 690
128. A.L. Jackman, W. Gibson, M. Brown, R. Kimbell, and F.T. Boyle The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694 Adv. Exp. Med. Biol. 339 1993 265 276
129. A.L. Jackman, G.A. Taylor, W. Gibson, R. Kimbell, M. Brown, A.H. Calvert, I.R. Judson, and L.R. Hughes ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study Cancer Res. 51 1991 5579 5586
130. G. Jansen, R. Mauritz, S. Drori, H. Sprecher, I. Kathmann, M. Bunni, D.G. Priest, P. Noordhuis, J.H. Schornagel, H.M. Pinedo, G.J. Peters, and Y.G. Assaraf A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance J. Biol. Chem. 273 1998 30189 30198
131. C.H. Jenh, P.K. Geyer, F. Baskin, and L.F. Johnson Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines Mol. Pharmacol. 28 1985 80 85
132. L.J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, and C. von Mering STRING 8 - a global view on proteins and their functional interactions in 630 organisms Nucleic Acids Res. 37 2009 D412 D416
133. S.A. Jensen, and J.B. Sorensen Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Cancer Chemother. Pharmacol. 58 2006 487 493
134. J. Ju, J. Pedersen-Lane, F. Maley, and E. Chu Regulation of p53 expression by thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 96 1999 3769 3774
135. H. Juarez-Salinas, J.L. Sims, and M.K. Jacobson Poly(ADP-ribose) levels in carcinogen-treated cells Nature 282 1979 740 741
136. S. Kammler, S. Lykke-Andersen, and T.H. Jensen The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells Mol. Cancer Res. 6 2008 990 995
137. C.M. Kane, and S. Linn Purification and characterization of an apurinic/apyrimidinic endonuclease from HeLa cells J. Biol. Chem. 256 1981 3405 3414
138. M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe Data, information, knowledge and principle: back to metabolism in KEGG Nucleic Acids Res. 42 2014 D199 D205
139. K.A. Kang, M.J. Piao, K.C. Kim, H.K. Kang, W.Y. Chang, I.C. Park, Y.S. Keum, Y.J. Surh, and J.W. Hyun Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation Cell Death Dis. 5 2014 e1183
140. K. Katakura, H. Fujise, K. Takeda, O. Kaneko, M. Torii, M. Suzuki, K.P. Chang, and Y. Hashiguchi Overexpression of LaMDR2, a novel multidrug resistance ATP-binding cassette transporter, causes 5-fluorouracil resistance in Leishmania amazonensis FEBS Lett. 561 2004 207 212
141. Y. Kaufman, S. Drori, P.D. Cole, B.A. Kamen, J. Sirota, I. Ifergan, M.W. Arush, R. Elhasid, D. Sahar, G.J. Kaspers, G. Jansen, L.H. Matherly, G. Rechavi, A. Toren, and Y.G. Assaraf Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia Cancer 100 2004 773 782
142. Y. Kaufman, I. Ifergan, L. Rothem, G. Jansen, and Y.G. Assaraf Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss Blood 107 2006 3288 3294
143. A. Kawahara, Y. Akagi, S. Hattori, T. Mizobe, K. Shirouzu, M. Ono, T. Yanagawa, M. Kuwano, and M. Kage Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer J. Clin. Pathol. 62 2009 364 369
144. H. Kawate, D.M. Landis, and L.A. Loeb Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine J. Biol. Chem. 277 2002 36304 36311
145. C. Kelly, N. Bhuva, M. Harrison, A. Buckley, and M. Saunders Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history Eur. J. Cancer 49 2013 2303 2310
146. M.E. Kitchens, A.M. Forsthoefel, K.W. Barbour, H.T. Spencer, and F.G. Berger Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability Mol. Pharmacol. 56 1999 1063 1070
147. M.E. Kitchens, A.M. Forsthoefel, Z. Rafique, H.T. Spencer, and F.G. Berger Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation J. Biol. Chem. 274 1999 12544 12547
148. S.E. Koehler, and R.D. Ladner Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition Mol. Pharmacol. 66 2004 620 626
149. C.H. Kohne, J. De Greve, J.T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, C. Bokemeyer, P. Reimer, H. Link, E. Spath-Schwalbe, H.J. Wilke, H. Bleiberg, J. Van Den Brande, M. Debois, U. Bethe, and E. Van Cutsem Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann. Oncol. 19 2008 920 926
150. C.H. Kohne, P. Thuss-Patience, M. Friedrich, P.T. Daniel, A. Kretzschmar, T. Benter, B. Bauer, R. Dietz, and B.s. Dorken Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity Br. J. Cancer 77 1998 973 977
151. K.V. Kosuri, X. Wu, L. Wang, M.A. Villalona-Calero, and G.A. Otterson An epigenetic mechanism for capecitabine resistance in mesothelioma Biochem. Biophys. Res. Commun. 391 2010 1465 1470
152. L.M. Krug, C.G. Azzoli, M.G. Kris, V.A. Miller, N.Z. Khokhar, W. Tong, M.S. Ginsberg, E. Venkatraman, L. Tyson, B. Pizzo, V. Baez, K.K. Ng, and F.M. Sirotnak 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer Clin. Cancer Res. 9 2003 2072 2078
153. L.M. Krug, K.K. Ng, M.G. Kris, V.A. Miller, W. Tong, R.T. Heelan, L. Leon, D. Leung, J. Kelly, S.C. Grant, and F.M. Sirotnak Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate Clin. Cancer Res. 6 2000 3493 3498
154. H. Kusuhara, Y.H. Han, M. Shimoda, E. Kokue, H. Suzuki, and Y. Sugiyama Reduced folate derivatives are endogenous substrates for cMOAT in rats Am. J. Physiol. 275 1998 G789 G796
155. D.M. Landis, J.L. Gerlach, E.T. Adman, and L.A. Loeb Tolerance of 5-fluorodeoxyuridine resistant human thymidylate synthases to alterations in active site residues Nucleic Acids Res. 27 1999 3702 3711
156. D.M. Landis, C.C. Heindel, and L.A. Loeb Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase Cancer Res. 61 2001 666 672
157. D.M. Landis, and L.A. Loeb Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases J. Biol. Chem. 273 1998 25809 25817
158. C.P. Leamon Folate-targeted drug strategies for the treatment of cancer Curr. Opin. Investig. Drugs 9 2008 1277 1286
159. K.H. Lee, H.S. Hur, S.A. Im, J. Lee, H.P. Kim, Y.K. Yoon, S.W. Han, S.H. Song, D.Y. Oh, T.Y. Kim, and Y.J. Bang RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase Cancer Lett. 299 2010 22 28
160. L. Li, S.H. Berger, and M.D. Wyatt Involvement of base excision repair in response to therapy targeted at thymidylate synthase Mol. Cancer Ther. 3 2004 747 753
161. Q. Li, C. Boyer, J.Y. Lee, and H.M. Shepard A novel approach to thymidylate synthase as a target for cancer chemotherapy Mol. Pharmacol. 59 2001 446 452
162. J. Liang, and J.M. Slingerland Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression Cell Cycle 2 2003 339 345
163. J.T. Liang, K.C. Huang, Y.M. Cheng, H.C. Hsu, A.L. Cheng, C.H. Hsu, K.H. Yeh, S.M. Wang, and K.J. Chang P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection Int. J. Cancer 97 2002 451 457
164. E. Liani, L. Rothem, M.A. Bunni, C.A. Smith, G. Jansen, and Y.G. Assaraf Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines Int. J. Cancer 103 2003 587 599
165. A. Ligabue, G. Marverti, U. Liebl, and H. Myllykallio Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression PLoS One 7 2012 e47318
166. T. Lindahl DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision-repair Prog. Nucleic Acid Res. Mol. Biol. 22 1979 135 192
167. Y. Liu, W. Wu, W. Hong, X. Sun, J. Wu, and Q. Huang Raltitrexed-based chemotherapy for advanced colorectal cancer Clin. Res. Hepatol. Gastroenterol. 38 2014 219 225
168. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 2003 330 338
169. M. Loriga, S. Piras, G. Paglietti, M.P. Costi, and A. Venturelli Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities Farmaco 58 2003 51 61
170. K.E. Lowe, C.B. Osborne, B.F. Lin, J.S. Kim, J.C. Hsu, and B. Shane Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism J. Biol. Chem. 268 1993 21665 21673
171. B. Lu, L. Wang, C. Stehlik, D. Medan, C. Huang, S. Hu, F. Chen, X. Shi, and Y. Rojanasakul Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells J. Immunol. 176 2006 6785 6793
172. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, and J.P. Neijt Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
173. M. Luo, and M.R. Kelley Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone Anticancer Res. 24 2004 2127 2134
174. Y. Luo, M. Walla, and M.D. Wyatt Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase DNA Repair (Amst.) 7 2008 162 169
175. G. Lurje, P.C. Manegold, Y. Ning, A. Pohl, W. Zhang, and H.J.s. Lenz Thymidylate synthase gene variations: predictive and prognostic markers Mol. Cancer Ther. 8 2009 1000 1007
176. J.R. Mackey, L.L. Jennings, M.L. Clarke, C.L. Santos, L. Dabbagh, M. Vsianska, S.L. Koski, R.W. Coupland, S.A. Baldwin, J.D. Young, and C.E. Cass Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers Clin. Cancer Res. 8 2002 110 116
177. S. Maddika, S.R. Ande, E. Wiechec, L.L. Hansen, S. Wesselborg, and M. Los Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis J. Cell Sci. 121 2008 979 988
178. S. Maddika, G.H. Bay, T.J. Kroczak, S.R. Ande, S. Maddika, E. Wiechec, S.B. Gibson, and M. Los Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death Cell Prolif. 40 2007 835 848
179. S.M. Malik, K. Liu, X. Qiang, R. Sridhara, S. Tang, W.D. McGuinn Jr., S.L. Verbois, A. Marathe, G.M. Williams, J. Bullock, C. Tornoe, S.C. Lin, T. Ocheltree, M. Vialpando, A. Kacuba, R. Justice, and R. Pazdur Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary Clin. Cancer Res. 16 2010 4921 4927
180. E. Marchi, M. Mangone, K. Zullo, and O.A. O'Connor Pralatrexate pharmacology and clinical development Clin. Cancer Res. 19 2013 6657 6661
181. G. Marverti, G. Guaitoli, A. Ligabue, C. Frassineti, M.G. Monti, P. Lombardi, and M.P. Costi Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells Amino Acids 42 2012 641 653
182. G. Marverti, A. Ligabue, P. Lombardi, S. Ferrari, M.G. Monti, C. Frassineti, and M.P. Costi Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells Int. J. Oncol. 43 2013 1269 1280
183. G. Marverti, A. Ligabue, G. Paglietti, P. Corona, S. Piras, G. Vitale, D. Guerrieri, R. Luciani, M.P. Costi, C. Frassineti, and M.S. Moruzzi Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells Eur. J. Pharmacol. 615 2009 17 26
184. J.F. Mata, J.M. Garcia-Manteiga, M.P. Lostao, S. Fernandez-Veledo, E. Guillen-Gomez, I.M. Larrayoz, J. Lloberas, F.J. Casado, and M. Pastor-Anglada Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug Mol. Pharmacol. 59 2001 1542 1548
185. U.A. Matulonis, N.S. Horowitz, S.M. Campos, H. Lee, J. Lee, C.N. Krasner, S. Berlin, M.R. Roche, L.R. Duska, L. Pereira, D. Kendall, and R.T. Penson Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer J. Clin. Oncol. 26 2008 5761 5766
186. R. Mauritz, G.J. Peters, D.G. Priest, Y.G. Assaraf, S. Drori, I. Kathmann, P. Noordhuis, M.A. Bunni, A. Rosowsky, J.H. Schornagel, H.M. Pinedo, and G. Jansen Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis Biochem. Pharmacol. 63 2002 105 115
187. M.W. McBurney, and G.F. Whitmore Mechanism of growth inhibition by methotrexate Cancer Res. 35 1975 586 590
188. D.E. McCloskey, J.J. McGuire, C.A. Russell, B.G. Rowan, J.R. Bertino, G. Pizzorno, and E. Mini Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines J. Biol. Chem. 266 1991 6181 6187
189. J.J. McGuire Antifolate polyglutamation in preclinical and clinical antifolate resistance J. AL, Anticancer Drug Developments Guide: Antifolate Drugs in Cancer Therapy 1999 339 363
190. D.R. McNeill, W. Lam, T.L. DeWeese, Y.C. Cheng, and D.M. Wilson 3rd Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites Mol. Cancer Res. 7 2009 897 906
191. M. Meyers, M.W. Wagner, H.S. Hwang, T.J. Kinsella, and D.A. Boothman Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses Cancer Res. 61 2001 5193 5201
192. M. Meyers, M.W. Wagner, A. Mazurek, C. Schmutte, R. Fishel, and D.A. Boothman DNA mismatch repair-dependent response to fluoropyrimidine-generated damag J. Biol. Chem. 280 2005 5516 5526
193. G. Milano, M.C. Etienne, V. Pierrefite, M. Barberi-Heyob, R. Deporte-Fety, and N. Renee Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity Br. J. Cancer 79 1999 627 630
194. D.S. Miller, J.A. Blessing, C.N. Krasner, R.S. Mannel, P. Hanjani, M.L. Pearl, S.E. Waggoner, and C.H. Boardman Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J. Clin. Oncol. 27 2009 2686 2691
195. R.E. Miller, and S. Banerjee The current state of pemetrexed in ovarian cancer Expert Opin. Investig. Drugs 22 2013 1201 1210
196. S. Miyahara, H. Miyakoshi, T. Yokogawa, K.T. Chong, J. Taguchi, T. Muto, K. Endoh, W. Yano, T. Wakasa, H. Ueno, Y. Takao, A. Fujioka, A. Hashimoto, K. Itou, K. Yamamura, M. Nomura, H. Nagasawa, S. Shuto, and M. Fukuoka Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors J. Med. Chem. 55 2012 2970 2980
197. M. Molina-Arcas, G. Moreno-Bueno, P. Cano-Soldado, H. Hernandez-Vargas, F.J. Casado, J. Palacios, and M. Pastor-Anglada Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells Biochem. Pharmacol. 72 2006 1646 1656
198. R.G. Moran, M. Mulkins, and C. Heidelberger Role of thymidylate synthetase activity in development of methotrexate cytotoxicity Proc. Natl. Acad. Sci. U.S.A. 76 1979 5924 5928
199. S. Murphy, G. Probert, J. Anderson, S. Pollock, I. Taylor, H. Clague, and K. Sridharan Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival Clin. Oncol. (R. Coll. Radiol.) 25 2013 713 718
200. E.M. Newman, Y. Lu, M. Kashani-Sabet, V. Kesavan, and K.J. Scanlon Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin Biochem. Pharmacol. 37 1988 443 447
201. D. Nimbalkar, M.K. Henry, and F.W. Quelle Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death Cancer Res. 63 2003 1034 1039
202. G. Nishimura, I. Terada, T. Kobayashi, I. Ninomiya, H. Kitagawa, S. Fushida, T. Fujimura, M. Kayahara, K. Shimizu, T. Ohta, and K. Miwa Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy Oncol. Rep. 9 2002 479 482
203. I. Nishisho, N. Kikkawa, T. Ebata, H. Osanai, S. Ujiie, Y. Mitachi, M. Tsutsui, K. Sawai, Y. Nishiguchi, K. Yasutake, H. Wakasugi, and A. Wakui A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer Gan To Kagaku Ryoho. 27 2000 81 91
204. O.A. O'Connor, P.A. Hamlin, C. Portlock, C.H. Moskowitz, A. Noy, D.J. Straus, B. Macgregor-Cortelli, E. Neylon, D. Sarasohn, O. Dumetrescu, D.R. Mould, M. Fleischer, A.D. Zelenetz, F. Sirotnak, and S. Horwitz Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma Br. J. Haematol. 139 2007 425 428
205. O.A. O'Connor, S. Horwitz, P. Hamlin, C. Portlock, C.H. Moskowitz, D. Sarasohn, E. Neylon, J. Mastrella, R. Hamelers, B. Macgregor-Cortelli, M. Patterson, V.E. Seshan, F. Sirotnak, M. Fleisher, D.R. Mould, M. Saunders, and A.D. Zelenetz Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies J. Clin. Oncol. 27 2009 4357 4364
206. T. Oguri, Y. Bessho, H. Achiwa, H. Ozasa, K. Maeno, H. Maeda, S. Sato, and R. Ueda MRP8/ABCC11 directly confers resistance to 5-fluorouracil Mol. Cancer Ther. 6 2007 122 127
207. A. Ooyama, Y. Okayama, T. Takechi, Y. Sugimoto, T. Oka, and M. Fukushima Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs Cancer Sci. 98 2007 577 583
208. C.E. Paiva, B.S. Paiva, R. Garita, O.C. Michelin, and K. Okoshi Acute coronary syndrome associated with continuous 5-fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma J. Gastrointest. Cancer 40 2009 133 137
209. J.W. Park, S.C. Kim, W.K. Kim, J.P. Hong, K.H. Kim, H.Y. Yeo, J.Y. Lee, M.S. Kim, J.H. Kim, S.Y. Yang, D.Y. Kim, J.H. Oh, J.Y. Cho, and B.C. Yoo Expression of phosphoenolpyruvate carboxykinase linked to chemoradiation susceptibility of human colon cancer cells BMC Cancer 14 2014 160
210. J.R.s. Patton Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine Biochemistry 32 1993 8939 8944
211. M. Pelà, P. Saxena, R. Luciani, M. Santucci, S. Ferrari, G. Marverti, C. Marraccini, A. Martello, S. Pirondi, F. Genovese, S. Salvadori, D. D'Arca, G. Ponterini, M.P. Costi, and R. Guerrini Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth J. Med. Chem. 57 2014 1355 1367
212. M.M. Pena, Y.Y. Xing, S. Koli, and F.G. Berger Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase Biochem. J. 394 2006 355 363
213. M.A. Perez-Moreno, M. Galvan-Banqueri, S. Flores-Moreno, A. Villalba-Moreno, J. Cotrina-Luque, and F.J. Bautista-Paloma Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer Int. J. Clin. Pharm. 36 2014 476 487
214. G.J. Peters, H.H. Backus, S. Freemantle, B. van Triest, G. Codacci-Pisanelli, C.L. van der Wilt, K. Smid, J. Lunec, A.H. Calvert, S. Marsh, H.L. McLeod, E. Bloemena, S. Meijer, G. Jansen, C.J. van Groeningen, and H.M. Pinedo Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism Biochim. Biophys. Acta 1587 2002 194 205
215. J. Phan, S. Koli, W. Minor, R.B. Dunlap, S.H. Berger, and L. Lebioda Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug Biochemistry 40 2001 1897 1902
216. J. Phan, D.J. Steadman, S. Koli, W.C. Ding, W. Minor, R.B. Dunlap, S.H. Berger, and L. Lebioda Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors J. Biol. Chem. 276 2001 14170 14177
217. K. Pietras, T. Sjoblom, K. Rubin, C.H. Heldin, and A. Ostman PDGF receptors as cancer drug targets Cancer Cell 3 2003 439 443
218. S. Piras, M. Loriga, and G. Paglietti Quinoxaline chemistry. Part XVII. Methyl [4-(substituted 2-quinoxalinyloxy) phenyl] acetates and ethyl N-([4-(substituted 2-quinoxalinyloxy) phenyl] acetyl) glutamates analogs of methotrexate: synthesis and evaluation of in vitro anticancer activity Farmaco 59 2004 185 194
219. S. Piras, M. Loriga, A. Carta, G. Paglietti, M.P. Costi, and S. Ferrari Novel 3 benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents J. Heterocycl. Chem. 43 2006 541 551
220. A. Planting, M. de Jong, P. Jansen, J. Kerrebijn, M. Smith, and J. Verweij Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer Eur. J. Cancer 41 2005 93 97
221. E.C. Popa, and M.A. Shah Capecitabine in the treatment of esophageal and gastric cancers Expert Opin. Investig. Drugs 22 2013 1645 1657
222. P.D. Prasad, S. Ramamoorthy, F.H. Leibach, and V. Ganapathy Molecular cloning of the human placental folate transporter Biochem. Biophys. Res. Commun. 206 1995 681 687
223. S. Pratt, R.L. Shepard, R.A. Kandasamy, P.A. Johnston, W. Perry 3rd, and A.H. Dantzig The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites Mol. Cancer Ther. 4 2005 855 863
224. J.B. Prins, A.W. Langerak, R.P. Dirks, C.A. Van der Linden-Van Beurden, P.A. De Laat, H.P. Bloemers, and M.A. Versnel Identification of regulatory sequences in the promoter of the PDGF B-chain gene in malignant mesothelioma cell lines Biochim. Biophys. Acta 1317 1996 223 232
225. S.M. Pulukuri, J.A. Knost, N. Estes, and J.S. Rao Small interfering RNA-directed knockdown of uracil DNA glycosylase induces apoptosis and sensitizes human prostate cancer cells to genotoxic stress Mol. Cancer Res. 7 2009 1285 1293
226. S.K. Quinney, S.P. Sanghani, W.I. Davis, T.D. Hurley, Z. Sun, D.J. Murry, and W.F. Bosron Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide J. Pharmacol. Exp. Ther. 313 2005 1011 1016
227. A.C. Racanelli, S.B. Rothbart, C.L. Heyer, and R.G. Moran Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition Cancer Res. 69 2009 5467 5474
228. L. Rahman, D. Voeller, M. Rahman, S. Lipkowitz, C. Allegra, J.C. Barrett, F.J. Kaye, and M. Zajac-Kaye Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme Cancer Cell 5 2004 341 351
229. D. Raina, R. Ahmad, S. Kumar, J. Ren, K. Yoshida, S. Kharbanda, and D. Kufe MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage EMBO J. 25 2006 3774 3783
230. D. Ransom, K. Wilson, M. Fournier, R.J. Simes, V. Gebski, D. Yip, N. Tebbutt, C.S. Karapetis, D. Ferry, S. Gordon, and T.J. Price Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines Ann. Oncol. 25 2014 117 121
231. S. Raz, M. Stark, and Y.G. Assaraf Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia Oncotarget 5 2014 9183 9198
232. R.T. Reilly, A.M. Forsthoefel, and F.G. Berger Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase Arch. Biochem. Biophys. 342 1997 338 343
233. N. Ribelles, J. Lopez-Siles, A. Sanchez, E. Gonzalez, M.J. Sanchez, F. Carabantes, P. Sanchez-Rovira, A. Marquez, R. Duenas, I. Sevilla, and E. Alba A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression Curr. Drug Metab. 9 2008 336 343
234. D.A. Richards, D. Loesch, S.J. Vukelja, H. Wu, W.J. Hyman, J. Nieves, Y. Wang, S. Hu, O.O. Shonukan, and D.F. Tai Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer Invest. New Drugs 29 2011 963 970
235. E. Rivera, and H. Gomez Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Breast Cancer Res. 12 Suppl. 2 2010 S2
236. B.W. Robinson, and R.A. Lake Advances in malignant mesothelioma N. Engl. J. Med. 353 2005 1591 1603
237. H.M. Robinson, R. Jones, M. Walker, G. Zachos, R. Brown, J. Cassidy, and D.A. Gillespie Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil Oncogene 25 2006 5359 5369
238. A.L. Rodd, K. Ververis, and T.C. Karagiannis Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma Clin. Med. Insights Oncol. 6 2012 305 314
239. S. Rossi Australian Medicines Handbook 2013 Australian Medicines Handbook Adelaide
240. S.B. Rothbart, A.C. Racanelli, and R.G. Moran Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas Cancer Res. 70 2010 10299 10309
241. L. Rothem, A. Aronheim, and Y.G. Assaraf Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells J. Biol. Chem. 278 2003 8935 8941
242. L. Rothem, I. Ifergan, Y. Kaufman, D.G. Priest, G. Jansen, and Y.G. Assaraf Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines Biochem. J. 367 2002 741 750
243. L. Rothem, M. Stark, and Y.G. Assaraf Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene Mol. Pharmacol. 66 2004 1536 1543
244. L. Rothem, M. Stark, Y. Kaufman, L. Mayo, and Y.G. Assaraf Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation J. Biol. Chem. 279 2004 374 384
245. M.G. Rots, R. Pieters, G.J. Peters, P. Noordhuis, C.H. van Zantwijk, G.J. Kaspers, K. Hahlen, U. Creutzig, A.J. Veerman, and G. Jansen Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia Blood 93 1999 1677 1683
246. K. Roy, K. Mitsugi, S. Sirlin, B. Shane, and F.M. Sirotnak Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription J. Biol. Chem. 270 1995 26918 26922
247. M.W. Saif, M.M. Shah, and A.R. Shah Fluoropyrimidine-associated cardiotoxicity: revisited Expert Opin. Drug Saf. 8 2009 191 202
248. K. Saito, K. Khan, S.Z. Yu, S. Ronson, J. Rhee, G. Li, D. Van Echo, M. Suntharalingam, B.W. O'Malley Jr., and D. Li The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer Laryngoscope 119 2009 82 88
249. J. Salgado, N. Zabalegui, C. Gil, I. Monreal, J. Rodriguez, and J. Garcia-Foncillas Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer Oncol. Rep. 17 2007 325 328
250. O.M. Salo-Ahen, and R.C. Wade The active-inactive transition of human thymidylate synthase: targeted molecular dynamics simulations Proteins 79 2011 2886 2899
251. D. Salonga, K.D. Danenberg, M. Johnson, R. Metzger, S. Groshen, D.D. Tsao-Wei, H.J. Lenz, C.G. Leichman, L. Leichman, R.B. Diasio, and P.V. Danenberg Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin. Cancer Res. 6 2000 1322 1327
252. O.J. Sansom, J. Zabkiewicz, S.M. Bishop, J. Guy, A. Bird, and A.R. Clarke MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine Oncogene 22 2003 7130 7136
253. D. Sargent, A. Sobrero, A. Grothey, M.J. O'Connell, M. Buyse, T. Andre, Y. Zheng, E. Green, R. Labianca, C. O'Callaghan, J.F. Seitz, G. Francini, D. Haller, G. Yothers, R. Goldberg, and A. de Gramont Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials J. Clin. Oncol. 27 2009 872 877
254. A.D. Sasse, S.E.C., L.V. Dos Santos, J.S. Lima, C.M. Nascente, H.P. Saito, M.S. Tariki, V.C. Conceicao, A.M. Carvalho, and N.S. Siqueira Oral fluoropyrimidines vs 5-fluorouracil for colorectal cancer: results of a systematic review and meta-analysis J. Clin. Oncol. (ASCO Annu. Meet. Proc.) 27 2009 4111
255. G.V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J.S. Lee, A. Mellemgaard, K. Park, S. Patil, J. Rolski, T. Goksel, F. de Marinis, L. Simms, K.P. Sugarman, and D. Gandara Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pem etrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J. Clin. Oncol. 26 2008 3543 3551
256. K.J. Scanlon, and M. Kashani-Sabet Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells Proc. Natl. Acad. Sci. U.S.A. 85 1988 650 653
257. U. Scherf, D.T. Ross, M. Waltham, L.H. Smith, J.K. Lee, L. Tanabe, K.W. Kohn, W.C. Reinhold, T.G. Myers, D.T. Andrews, D.A. Scudiero, M.B. Eisen, E.A. Sausville, Y. Pommier, D. Botstein, P.O. Brown, and J.N. Weinstein A gene expression database for the molecular pharmacology of cancer Nat. Genet. 24 2000 236 244
258. J.C. Schmitz, T.M. Chen, and E. Chu Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds Cancer Res. 64 2004 1431 1435
259. V. Schreiber, J.C. Ame, P. Dolle, I. Schultz, B. Rinaldi, V. Fraulob, J. Menissier-de Murcia, and G. de Murcia Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1 J. Biol. Chem. 277 2002 23028 23036
260. J. Schuller, J. Cassidy, E. Dumont, B. Roos, S. Durston, L. Banken, M. Utoh, K. Mori, E. Weidekamm, and B.s. Reigner Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother. Pharmacol. 45 2000 291 297
261. R.M. Schultz, V.F. Patel, J.F. Worzalla, and C. Shih Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514 Anticancer Res. 19 1999 437 443
262. W.A. Schulz, C. Steinhoff, and A.R. Florl Methylation of endogenous human retroelements in health and disease Curr. Top. Microbiol. Immunol. 310 2006 211 250
263. O.C. Schuurbiers, J.H. Kaanders, H.F. van der Heijden, R.P. Dekhuijzen, W.J. Oyen, and J. Bussink The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer J. Thorac. Oncol. 4 2009 761 767
264. G.K. Schwartz, A. Harstrick, and M. Gonzalez Baron Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials Eur. J. Cancer 35 Suppl. 1 1999 S9 S13
265. J. Sehouli, A.M. Alvarez, S. Manouchehrpour, P. Ghatage, C. Szczylik, A. Zimmermann, T. Bauknecht, K.Y. Look, and G. Oskay-Oezcelik A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer Gynecol. Oncol. 124 2012 205 209
266. C. Serdjebi, G. Milano, and J. Ciccolini Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs Expert Opin. Drug Metab. Toxicol. 11 2015 665 672
267. A. Shafran, I. Ifergan, E. Bram, G. Jansen, I. Kathmann, G.J. Peters, R.W. Robey, S.E. Bates, and Y.G.s. Assaraf ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates Cancer Res. 65 2005 8414 8422
268. J.D. Shapiro, M.J. Millward, D. Rischin, M. Michael, V. Walcher, P.A. Francis, and G.C. Toner Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol. Oncol. 63 1996 89 93
269. L.X. Shi, R. Ma, R. Lu, Q. Xu, Z.F. Zhu, L. Wang, C.L. Zhou, X.L. Li, H.L. Zhang, and Z. Yao Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU Cancer Lett. 269 2008 101 110
270. X. Shi, S. Liu, J. Kleeff, H. Friess, and M.W. Buchler Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes Oncology 62 2002 354 362
271. C. Shih, V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, L.L. Habeck, K.A. Shackelford, L.G. Mendelsohn, D.J. Soose, V.F. Patel, S.L. Andis, J.R. Bewley, E.A. Rayl, B.A. Moroson, G.P. Beardsley, W. Kohler, M. Ratnam, and R.M. Schultz LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res. 57 1997 1116 1123
272. Y.K. Shin, B.C. Yoo, H.J. Chang, E. Jeon, S.H. Hong, M.S. Jung, S.J. Lim, and J.G. Park Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance Cancer Res. 65 2005 3162 3170
273. Y.K. Shin, B.C. Yoo, Y.S. Hong, H.J. Chang, K.H. Jung, S.Y. Jeong, and J.G. Park Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance Electrophoresis 30 2009 2182 2192
274. T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, K. Yonekura, and M. Fukushima Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 1996 548 557
275. T. Shirasaki, S. Maruya, H. Mizukami, S. Kakehata, H. Kurotaki, S. Yagihashi, and H. Shinkawa Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma BMC Cancer 8 2008 348
276. M. Showkat, M.A. Beigh, and K.I. Andrabi mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions Mol. Biol. Int. 2014 2014 686984
277. J. Sigmond, H.H. Backus, D. Wouters, O.H. Temmink, G. Jansen, and G.J. Peters Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression Biochem. Pharmacol. 66 2003 431 438
278. R.A. Silverstein, E. Gonzalez de Valdivia, and N. Visa The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6 Mol. Cancer Res. 9 2011 332 340
279. F.M. Sirotnak, J.I. DeGraw, W.T. Colwell, and J.R. Piper A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice Cancer Chemother. Pharmacol. 42 1998 313 318
280. P.G. Smith, E. Marshman, A.H. Calvert, D.R. Newell, and N.J. Curtin Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines Semin. Oncol. 26 1999 63 67
281. R. Sowers, B.D. Wenzel, C. Richardson, P.A. Meyers, J.H. Healey, A.S. Levy, and R. Gorlick Impairment of methotrexate transport is common in osteosarcoma tumor samples Sarcoma 2011 2011 834170
282. J.L. Speyer, J.M. Collins, R.L. Dedrick, M.F. Brennan, A.R. Buckpitt, H. Londer, V.T. DeVita Jr., and C.E. Myers Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally Cancer Res. 40 1980 567 572
283. M. Stark, and Y.G. Assaraf Loss of Sp1 function via inhibitory phosphorylation in antifolate-resistant human leukemia cells with down-regulation of the reduced folate carrier Blood 107 2006 708 715
284. M. Stark, E.E. Bram, M. Akerman, Y. Mandel-Gutfreund, and Y.G. Assaraf Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance J. Biol. Chem. 286 2011 3741 3754
285. M. Stark, C. Wichman, I. Avivi, and Y.G. Assaraf Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia Blood 113 2009 4362 4369
286. R.M. Stroud, and J.S. Finer-Moore Conformational dynamics along an enzymatic reaction pathway: thymidylate synthase, "the movie" Biochemistry 42 2003 239 247
287. S. Sweetman The Complete Drug Reference 2011 Martindale
288. A. Tajima, M.T. Hess, B.L. Cabrera, R.D. Kolodner, and J.M. Carethers The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance Gastroenterology 127 2004 1678 1684
289. K. Takezawa, I. Okamoto, W. Okamoto, M. Takeda, K. Sakai, S. Tsukioka, K. Kuwata, H. Yamaguchi, K. Nishio, and K. Nakagawa Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer Br. J. Cancer 104 2011 1594 1601
290. E.C. Taylor, D. Kuhnt, C. Shih, S.M. Rinzel, G.B. Grindey, J. Barredo, M. Jannatipour, and R.G. Moran A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase J. Med. Chem. 35 1992 4450 4454
291. A. Tochowicz, M. Santucci, P. Saxena, G. Guaitoli, M. Trande, J. Finer-Moore, R.M. Stroud, and M.P. Costi Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides J. Med. Chem. 58 2015 1012 1018
292. Y. Tong, H. Huang, and H. Pan Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 456 2015 86 91
293. Y. Tong, X. Liu-Chen, E.A. Ercikan-Abali, G.M. Capiaux, S.C. Zhao, D. Banerjee, and J.R. Bertino Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells J. Biol. Chem. 273 1998 11611 11618
294. Y. Tong, X. Liu-Chen, E.A. Ercikan-Abali, S.C. Zhao, D. Banerjee, F. Maley, and J.R. Bertino Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89 J. Biol. Chem. 273 1998 31209 31214
295. C. Tournigand, T. Andre, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, and A. de Gramont FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J. Clin. Oncol. 22 2004 229 237
296. A.S. Tsao, N. Harun, J.J. Lee, J. Heymach, K. Pisters, W.K. Hong, J. Fujimoto, and I. Wistuba Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma Clin. Lung Cancer 15 2014 197 201
297. Y. Tsukamoto, Y. Kato, M. Ura, I. Horii, H. Ishitsuka, H. Kusuhara, and Y. Sugiyama A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU Pharm. Res. 18 2001 1190 1202
298. T. Uemura, T. Oguri, H. Ozasa, O. Takakuwa, M. Miyazaki, K. Maeno, S. Sato, and R. Ueda ABCC11/MRP8 confers pemetrexed resistance in lung cancer Cancer Sci. 101 2010 2404 2410
299. S. Urba, C.M. van Herpen, T.P. Sahoo, D.M. Shin, L. Licitra, K. Mezei, C. Reuter, R. Hitt, F. Russo, S.C. Chang, A.M. Hossain, B. Frimodt-Moller, A. Koustenis, and R.L. Hong Pemetrexed in combination with cisplatin vs cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study Cancer 118 2012 4694 4705
300. E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn, J. McKendrick, B. Osterwalder, G. Perez-Manga, R. Rosso, P. Rougier, W.H. Schmiegel, J.F. Seitz, P. Thompson, J.M. Vieitez, C. Weitzel, and P. Harper Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J. Clin. Oncol. 19 2001 4097 4106
301. A.G. van Gorp, K.M. Pomeranz, K.U. Birkenkamp, R.C. Hui, E.W. Lam, and P.J. Coffer Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation Cancer Res. 66 2006 10760 10769
302. J.P. van Meerbeeck, R. Gaafar, C. Manegold, R.J. Van Klaveren, E.A. Van Marck, M. Vincent, C. Legrand, A. Bottomley, C. Debruyne, and G. Giaccone Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J. Clin. Oncol. 23 2005 6881 6889
303. I. Vergote, H. Calvert, M. Kania, C. Kaiser, A.H. Zimmermann, and J. Sehouli A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer Eur. J. Cancer 45 2009 1415 1423
304. E. Villafranca, Y. Okruzhnov, M.A. Dominguez, J. Garcia-Foncillas, I. Azinovic, E. Martinez, J.J. Illarramendi, F. Arias, R. Martinez Monge, E. Salgado, S. Angeletti, and A. Brugarolas Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer J. Clin. Oncol. 19 2001 1779 1786
305. M. Visentin, E.S. Unal, R. Zhao, and I.D. Goldman The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor Cancer Chemother. Pharmacol. 72 2013 597 606
306. D.M. Voeller, M. Zajac-Kaye, R.J. Fisher, and C.J. Allegra The identification of thymidylate synthase peptide domains located in the interface region that bind thymidylate synthase mRNA Biochem. Biophys. Res. Commun. 297 2002 24 31
307. B. Vogelstein Cancer. A deadly inheritance Nature 348 1990 681 682
308. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, and P. Paoletti Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma J. Clin. Oncol. 21 2003 2636 2644
309. C. von Mering, L.J. Jensen, B. Snel, S.D. Hooper, M. Krupp, M. Foglierini, N. Jouffre, M.A. Huynen, and P. Bork STRING: known and predicted protein-protein associations, integrated and transferred across organisms Nucleic Acids Res. 33 2005 D433 D437
310. D. Wang, M. Luo, and M.R. Kelley Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition Mol. Cancer Ther. 3 2004 679 686
311. L. Wang, B. Liu, T. Wang, Y. Ding, X. Qian, and Y. Zhao Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity Anticancer Res. 28 2008 1085 1091
312. T.L. Wang, L.A. Diaz Jr., K. Romans, A. Bardelli, S. Saha, G. Galizia, M. Choti, R. Donehower, G. Parmigiani, M. Shih Ie, C. Iacobuzio-Donahue, K.W. Kinzler, B. Vogelstein, C. Lengauer, and V.E. Velculescu Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients Proc. Natl. Acad. Sci. U.S.A. 101 2004 3089 3094
313. W. Wang, J. Cassidy, V. O'Brien, K.M. Ryan, and E. Collie-Duguid Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells Cancer Res. 64 2004 8167 8176
314. W. Wang, S. Marsh, J. Cassidy, and H.L. McLeod Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors Cancer Res. 61 2001 5505 5510
315. X. Wang, J. Xu, S. Ju, H. Ni, J. Zhu, and H. Wang Livin gene plays a role in drug resistance of colon cancer cells Clin. Biochem. 43 2010 655 660
316. Y. Wang, R. Zhao, and I.D. Goldman Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier Clin. Cancer Res. 10 2004 6256 6264
317. W.H. Ward, R. Kimbell, and A.L. Jackman Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase Biochem. Pharmacol. 43 1992 2029 2031
318. R.G. Watson, F. Muhale, L.B. Thorne, J. Yu, B.H. O'Neil, J.M. Hoskins, M.O. Meyers, A.M. Deal, J.G. Ibrahim, M.L. Hudson, C.M. Walko, H.L. McLeod, and J.T. Auman Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy Eur. J. Cancer 46 2010 3358 3364
319. S.D. Webley, S.J. Welsh, A.L. Jackman, and G.W. Aherne The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition Br. J. Cancer 85 2001 446 452
320. L.D. Weeks, P. Fu, and S.L. Gerson Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed Mol. Cancer Ther. 12 2013 2248 2260
321. S.J. Welsh, S. Hobbs, and G.W. Aherne Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition Eur. J. Cancer 39 2003 378 387
322. G.R. Westerhof, J.H. Schornagel, I. Kathmann, A.L. Jackman, A. Rosowsky, R.A. Forsch, J.B. Hynes, F.T. Boyle, G.J. Peters, and H.M. Pinedo Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity Mol. Pharmacol. 48 1995 459 471
323. J.C. White Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. Studies with pure enzyme and computer modeling using network thermodynamics J. Biol. Chem. 254 1979 10889 10895
324. J.C. White, and I.D. Goldman Methotrexate resistance in al L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport. Computer simulations based on network thermodynamics J. Biol. Chem. 256 1981 5722 5727
325. K.S. Wilson, and S.C. Malfair Taylor Raltitrexed: optimism and reality Expert Opin. Drug Metab. Toxicol. 5 2009 1447 1454
326. P.M. Wilson, P.V. Danenberg, P.G. Johnston, H.J. Lenz, and R.D. Ladner Standing the test of time: targeting thymidylate biosynthesis in cancer therapy Nat. Rev. Clin. Oncol. 11 2014 282 298
327. P.M. Wilson, M.J. LaBonte, H.J. Lenz, P.C. Mack, and R.D. Ladner Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer Mol. Cancer Ther. 11 2012 616 628
328. S.C. Wong, S.A. Proefke, A. Bhushan, and L.H. Matherly Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells J. Biol. Chem. 270 1995 17468 17475
329. J. Worm, A.F. Kirkin, K.N. Dzhandzhugazyan, and P. Guldberg Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells J. Biol. Chem. 276 2001 39990 40000
330. Z. Xiao, J. Xue, T.J. Sowin, and H. Zhang Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy Mol. Cancer Ther. 5 2006 1935 1943
331. C.H. Yam, T.K. Fung, and R.Y.s. Poon Cyclin A in cell cycle control and cancer Cell. Mol. Life Sci. 59 2002 1317 1326
332. T.L. Yang-Feng, Y.Y. Ma, R. Liang, P.D. Prasad, F.H. Leibach, and V. Ganapathy Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization Biochem. Biophys. Res. Commun. 210 1995 874 879
333. R. Yang, R. Sowers, B. Mazza, J.H. Healey, A. Huvos, H. Grier, M. Bernstein, G.P. Beardsley, M.D. Krailo, M. Devidas, J.R. Bertino, P.A. Meyers, and R. Gorlick Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples Clin. Cancer Res. 9 2003 837 844
334. T.Y. Yang, G.C. Chang, K.C. Chen, H.W. Hung, K.H. Hsu, G.T. Sheu, and S.L. Hsu Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells Eur. J. Pharmacol. 663 2011 17 26
335. R. Yasumatsu, T. Nakashima, H. Uryu, T. Ayada, T. Wakasaki, R. Kogo, M. Masuda, M. Fukushima, and S. Komune Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma Chemotherapy 55 2009 36 41
336. R. Yasumatsu, T. Nakashima, H. Uryu, M. Masuda, N. Hirakawa, H. Shiratsuchi, K. Tomita, M. Fukushima, and S. Komune The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells Oral Oncol. 45 2009 141 147
337. D. Yip, C. Karapetis, A. Strickland, C.B. Steer, and D. Goldstein Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Cochrane Database Syst. Rev. 2006 CD002093
338. B.C. Yoo, E. Jeon, S.H. Hong, Y.K. Shin, H.J. Chang, and J.G. Park Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line Clin. Cancer Res. 10 2004 4176 4184
339. Z. Zhan, K. He, D. Zhu, D. Jiang, Y.H. Huang, Y. Li, C. Sun, and Y.H. Jin Phosphorylation of Rad9 at serine 328 by cyclin A-Cdk2 triggers apoptosis via interfering Bcl-xL PLoS One 7 2012 e44923
340. B. Zhang, B. Zhang, X. Chen, S. Bae, K. Singh, M.K. Washington, and P.K. Datta Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway Br. J. Cancer 110 2014 946 957
341. N. Zhang, Y. Yin, S.J. Xu, and W.S. Chen 5-Fluorouracil: mechanisms of resistance and reversal strategies Molecules 13 2008 1551 1569
342. H. Zhao, J.B. French, Y. Fang, and S.J. Benkovic The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans Chem. Commun. (Camb.) 49 2013 4444 4452
343. R. Zhao, S. Babani, F. Gao, L. Liu, and I.D. Goldman The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate Clin. Cancer Res. 6 2000 3687 3695
344. R. Zhao, S. Chattopadhyay, M. Hanscom, and I.D. Goldman Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier Clin. Cancer Res. 10 2004 8735 8742
345. R. Zhao, M. Hanscom, S. Chattopadhyay, and I.D. Goldman Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway Cancer Res. 64 2004 3313 3319
346. R. Zhao, A. Qiu, E. Tsai, M. Jansen, M.H. Akabas, and I.D. Goldman The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier Mol. Pharmacol. 74 2008 854 862
347. H. Zhu, W. Guo, L. Zhang, J.J. Davis, F. Teraishi, S. Wu, X. Cao, J. Daniel, W.R. Smythe, and B. Fang Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells Mol. Cancer Ther. 4 2005 451 456
348. P.A. Zucali, E. Giovannetti, A. Destro, M. Mencoboni, G.L. Ceresoli, L. Gianoncelli, E. Lorenzi, F. De Vincenzo, M. Simonelli, M. Perrino, A. Bruzzone, E. Thunnissen, G. Tunesi, L. Giordano, M. Roncalli, G.J. Peters, and A. Santoro Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin Clin. Cancer Res. 17 2011 2581 2590